Stockscreener 앱 받기
524.99
0.13%
-0.68
시장 영업 전:
528.00
3.01
+0.57%
전일 마감가:
$525.67
열려 있는:
$532.1
하루 거래량:
302.71K
Relative Volume:
0.83
시가총액:
$12.04B
수익:
$958.40M
순이익/손실:
$-288.28M
주가수익비율:
-40.81
EPS:
-12.8641
순현금흐름:
$-193.02M
1주 성능:
+2.56%
1개월 성능:
+18.02%
6개월 성능:
+20.11%
1년 성능:
+62.88%
1일 변동 폭
$518.80
$539.16
1주일 범위
$503.93
$539.16
52주 변동 폭
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
524.99 | 11.92B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Grants Equity Awards to 20 New Employees - MyChesCo
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN
Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Its 20% Monthly Surge? - Yahoo Finance
Why (MDGL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Sahm
Madrigal Pharmaceuticals Inc (HAM:YDO1) Stock Price, Trades & News - GuruFocus
Fed Watch: What is the dividend yield of Madrigal Pharmaceuticals Inc2026 Market Overview & Growth Oriented Trading Recommendations - baoquankhu1.vn
Dip Buying: Is Madrigal Pharmaceuticals Inc stock good for income investors2026 Intraday Action & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Breakouts Watch: Can Madrigal Pharmaceuticals Inc weather a recession2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Madrigal Pharmaceuticals Grants Inducement Awards to New Employees - National Today
Madrigal Pharmaceuticals, Inc. (MDGL) stock price, news, quote and history - Yahoo Finance UK
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rheos Capital Works Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Winners Losers: Is now the right time to enter Madrigal Pharmaceuticals IncQuarterly Earnings Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) - MSN
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
MDGL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL - marketbeat.com
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference - MSN
Madrigal grants equity awards to seven new employees - MSN
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - Sahm
Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now? - bitget.com
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN
Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug - MSN
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance - Traders Union
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing - MSN
Loss Report: What are analysts price targets for Madrigal Pharmaceuticals Inc2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Insider Monkey
Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance
Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN
Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results - StocksToTrade
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
자본화:
|
볼륨(24시간):